For research use only. Not for therapeutic Use.
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo[1][2][3].
Midaglizole stimulates insulin release with the EC50 values of 200 nM, 24 µM for rat islets and MIN6 β-cell line, respectively[3].
Midaglizole (3, 30 mg/kg; i.v.) increases blood pressure in rats[1].
Midaglizole (0.2, 1, 2 mg/kg; infusion) reduces blood glucose levels in dags[2].
| Catalog Number | I032265 |
| CAS Number | 66529-17-7 |
| Synonyms | 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine |
| Molecular Formula | C16H17N3 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H17N3/c1-2-6-13(7-3-1)14(12-16-18-10-11-19-16)15-8-4-5-9-17-15/h1-9,14H,10-12H2,(H,18,19) |
| InChIKey | TYZQFNOLWJGHRZ-UHFFFAOYSA-N |
| SMILES | C1CN=C(N1)CC(C2=CC=CC=C2)C3=CC=CC=N3 |
| Reference | [1]. Hirohashi M, et al. Intrinsic pressor activity of midaglizole, an alpha-2 adrenoceptor antagonist, in pithed rats. Jpn J Pharmacol. 1990 Aug;53(4):519-20. [2]. Ohneda K, et al. Mechanism of insulin secretion by midaglizole. Diabetes Res Clin Pract. 1993 Feb;19(2):127-32. [3]. Proks P, et al. Inhibition of recombinant K(ATP) channels by the antidiabetic agents midaglizole, LY397364 and LY389382. Eur J Pharmacol. 2002 Sep 27;452(1):11-9. |
